Kymera Investor Presentation Deck

● First MDM2 Degrader, KT-253, in Clinic KT-253, unlike small molecule inhibitors, overcomes the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53 KT-253 inhibits tumor cell growth with picomolar potency and is more than 200-fold more potent than clinically active MDM2 small molecule inhibitors Broad franchise opportunities available for this mechanism (>50% tumors are p53 WT), Kymera is focused on indications with specific sensitivity to degrader mechanism, through a biomarker strategy Opportunity to translate clinically, as for IRAK4, superiority of degrader over SMI First patient dosed May 2023 • POM data expected in 2023 KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-class Opportunity to Address p53 WT Tumors Across a Variety of Tumor Types First degrader against a clinically proven but inadequately drugged target, MDM2 Profound single agent activity in preclinical liquid and solid tumor models Clinical development strategy includes accelerated registration path in p53 WT tumors with high sensitivity to degrader mechanism such as AML, lymphomas, and other solid tumors PAGE 58

View entire presentation